This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Whitehead, S. S.
Right arrow Articles by Murphy, B. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Whitehead, S. S.
Right arrow Articles by Murphy, B. R.

 Previous Article  |  Next Article 

J Virol, May 1998, p. 4467-4471, Vol. 72, No. 5
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Recombinant Respiratory Syncytial Virus (RSV) Bearing a Set of Mutations from Cold-Passaged RSV Is Attenuated in Chimpanzees

Stephen S. Whitehead,* Katalin Juhasz, Cai-Yen Firestone, Peter L. Collins, and Brian R. Murphy

Respiratory Viruses Section, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892-0720

Received 9 December 1997/Accepted 2 February 1998

    ABSTRACT
Top
Abstract
Text
References

A set of five missense mutations previously identified by nucleotide sequence analysis of subgroup A cold-passaged (cp) respiratory syncytial virus (RSV) has been introduced into a recombinant wild-type strain of RSV. This recombinant virus, designated rA2cp, appears to replicate less efficiently in the upper and lower respiratory tracts of seronegative chimpanzees than either biologically derived or recombinant wild-type RSV. Infection with rA2cp also resulted in significantly less rhinorrhea and cough than infection with wild-type RSV. These findings confirm the role of the cp mutations in attenuation of RSV and identify their usefulness for inclusion in future live attenuated recombinant RSV vaccine candidates.

    TEXT
Top
Abstract
Text
References

Infection with respiratory syncytial virus (RSV) remains the most common cause of serious viral bronchiolitis and pneumonia in infants and children worldwide. The age distribution of serious RSV-associated illness is unusual among the respiratory tract pathogens in that disease occurs most commonly during the first several months of life, despite the presence of maternally transmitted serum neutralizing antibodies (5). Respiratory tract disease occurs less frequently and is generally less severe during reinfection with RSV than following first infection (5). Furthermore, the initial infection with RSV confers a significant degree of protection, and serum and local antibodies have been found to be mediators of immunity to RSV (5). The primary goal of immunization with an RSV vaccine is to prevent the severe lower respiratory tract disease associated with first and second infections with RSV. Live attenuated RSV vaccines represent promising vaccine candidates for this purpose since (i) they can efficiently immunize in the presence of passively acquired RSV antibodies which are present in the target population, the very young infant (9); (ii) they induce both serum immunoglobulin G and local immunoglobulin A antibodies; and (iii) they do not cause immune response-mediated disease enhancement like that seen following immunization with formalin-inactivated RSV (3).

Since early work indicated that attenuated mutants of poliovirus and measles virus could be selected by growth at low temperature (20, 21), a cold-passaged RSV (cpRSV) subgroup A candidate was produced from the A2 strain of RSV by 52 passages in bovine embryonic kidney tissue culture at progressively lower temperatures, the final and lowest temperature being 26°C (12). cpRSV was shown to be completely attenuated in seropositive adults and children but still caused some moderate respiratory tract disease in RSV-seronegative infants (12, 16, 18). These studies with humans indicated that the biologically derived cpRSV vaccine candidate possessed an attenuation phenotype, and this was subsequently confirmed in seronegative chimpanzees (8). cpRSV lacks an in vitro marker of attenuation since the virus is neither significantly cold adapted nor temperature sensitive (ts) in tissue culture (6, 8, 12) and therefore exhibits the host range phenotype; i.e., its replication is permissive in tissue culture but restricted in humans and chimpanzees. The chimpanzee is the only experimental animal that can be used to assess this attenuation phenotype.

To better understand the genetic basis for the attenuation of cpRSV, the sequence of the entire genome was determined and compared to that of wild-type (wt) RSV strain A2 (6). At the time this sequencing project was initiated, the exact parent of cpRSV, which had been passaged five times in human embryonic kidney (HEK) tissue culture, no longer existed, but a derivative which had been further passaged two times in HEK tissue culture (HEK-7) was available. Sequence analysis of cpRSV and RSV HEK-7 showed that cpRSV had accumulated five nucleotide substitutions, one in the N gene, two in the F gene, and two in the L gene, resulting in five predicted amino acid substitutions (6, 10) (Table 1). The recent development of a system for recovery of infectious virus from cDNA clones of RSV permits us to identify the genetic basis of attenuation of RSV vaccine candidates, as well as to develop new vaccine candidates (4). Therefore, the goal of the present study was to determine if the set of five cp mutations, which have been identified by sequence analysis, indeed confers the attenuation phenotype. This is of particular importance because cpRSV was the parent for a series of further-attenuated RSV strains (described below), and thus the cp mutation set is a common feature of current RSV vaccine candidates.

The five cp mutations were introduced together into a modified cDNA representing the RSV subgroup A genome by using our previously described methods (15). The antigenome cDNA that was the starting material for these experiments was cDNA D46, from which RSV was first recovered in 1995 (4). cDNA D46 differed in two ways from the natural A2 isolate from which the cDNA was prepared. First, four restriction enzyme cleavage sites (marker mutations) (Table 1) were created by a single nucleotide insertion in the NS2-N intergenic region (IGR) and five nucleotide substitutions, two in the N-gene noncoding region, two in the G-F IGR, and one in the F-M2 IGR (4). Second, a G-to-C (negative-sense) substitution at nucleotide 4 in the leader region (the 4C mutation) (Table 1) was introduced since C at this position was previously found to be an up-regulator of RNA synthesis in an RSV minigenome system (13, 19a). This G-to-C substitution does not have an effect on the level of attenuation specified by a candidate RSV vaccine (11), an observation which is also confirmed here. Infectious virus recovered from this cDNA is designated rD46. cDNA D46 was then modified by the insertion of a set of six translationally silent restriction enzyme cleavage sites (site mutations) (Table 1) which were created in the L gene to act as genetic markers for identification of recombinant virus and to aid in future construction of L-gene mutants. This cDNA, designated D53sites, was used to generate the recombinant RSV rA2sites (15). Finally, the set of five cp mutations was introduced together with two additional mutations (HEK mutations) (Table 1) required to bring the F-gene coding region of the recombinant virus into agreement with that of RSV HEK-7. These two changes in F were made because alignment of the sequences of cDNA D46 and the HEK-passaged strain A2 RSV revealed two predicted amino acid substitutions in the F protein (6). These two F-gene changes are the only significant differences between the two passage levels of the RSV A2 isolates: the RSV A2 derivative, HEK-7, which has remained in a freezer for most of the last three decades, and the further-passaged RSV A2 that is in use in our laboratory, which is related to HEK-7 but which has undergone numerous rounds of plaque purification and propagation predominantly in HEp-2 cells. It is thus remarkable that the two viruses have so few differences. With the introduction of the two coding changes in F, the cDNA-encoded virus is identical at the amino acid level to HEK-7. Each of the cp and the two HEK mutations introduced into cDNA were genetically marked by an accompanying translationally silent restriction enzyme cleavage site addition or deletion. Virus recovered from this cDNA was designated rA2cp and contained the original 4C and marker mutations found in rD46, the six L-gene restriction site markers, the two HEK F-gene mutations, and the set of five cp mutations. The rD46, rA2sites, and rA2cp mutants, like their biologically derived counterparts, produced plaques efficiently on monolayers of tissue culture cells at 40°C and therefore are non-ts viruses.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   Mutations introduced into full-length cDNA clones used to create recombinant RSV

The attenuation phenotype of rA2cp was evaluated in RSV-seronegative chimpanzees as previously described (8) by comparing its levels of replication and pathogenicity with those of the rD46 and rA2sites wt recombinant viruses (Table 2). These findings, in turn, were compared to results from previous control studies with biologically derived cpRSV and wt RSV A2. Because of the severely limited number of available RSV-seronegative chimpanzees, test groups in this study were relatively small and limited to four animals. Upper respiratory tract (nasal wash) and lower respiratory tract (tracheal lavage) samples were collected over a period of 10 days, and the chimpanzees were monitored daily for symptoms of rhinorrhea and cough. To compare the levels of virus replication of wt and attenuated viruses, we determined mean peak titers and mean daily titers. Whereas the peak titers compare the maximum levels of virus replication achieved in each animal, the mean daily titers (see Table 2, footnote c, for definition) estimate the total extent of replication. We generally consider differences in mean titer greater than 10-fold as significant. Rhinorrhea scores (see Table 2, footnote d, for definition) and cough symptoms were also compared. We have defined mean rhinorrhea scores greater that 1.0 as significant and consider any day with coughing as significant. The three wt viruses, rD46, rA2sites, and biologically derived A2 wt, were comparable in their levels of virus replication and in the extent of illness they caused in chimpanzees (Table 2). Likewise, the levels of virus replication and illness in chimpanzees infected with rA2cp and the biologically derived cpRSV were similar. This is so despite the 28 nucleotide differences between the two viruses, which represent the silent changes purposefully introduced into rA2cp. Specifically, the mean peak or daily virus titers in either the upper or lower respiratory tract did not appear to be significantly different between rA2cp and biologically derived cpRSV. Importantly, each of the two cp viruses replicated less well and induced fewer symptoms than the wt viruses.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 2.   The set of five cp mutations attenuates RSV for the upper and lower respiratory tracts of chimpanzees

The rA2cp virus was directly compared with its most closely related recombinant wt virus, rA2sites. In the lower respiratory tract, the rA2cp mutant virus exhibited a 25-fold decrease in peak virus titer as well as a 10-fold decrease in mean daily virus titer compared to the titers for the rA2sites virus. In the upper respiratory tract, there were also modest 4- and 10-fold decreases in the peak virus titer and mean daily titer, respectively. In comparison with chimpanzees receiving wt rA2sites, those inoculated with rA2cp showed a marked decrease in rhinorrhea and cough. These findings with rA2cp demonstrate that the set of five cp mutations indeed specifies the host range, attenuation phenotype. Unfortunately, due to the limited availability of RSV-seronegative chimpanzees, it is not feasible at this time to examine the contribution of individual cp mutations to overall virus attenuation and prevention of illness associated with infection.

The design of these studies also allows for an evaluation of the effects of the other sets of introduced mutations on virus replication or illness. The original recombinant virus, rD46, was comparable in replication and virulence to the biologically derived A2 wt virus (Table 2, compare results for chimpanzees 1 to 4 with chimpanzees 5 and 6). This shows that this recombinant virus, on which all subsequent engineered viruses will be based, indeed is wt with respect to replication and virulence in a fully permissive experimental animal. Thus, it does not contain any incidental deleterious changes, and furthermore the four marker mutations and the 4C mutation do not significantly alter its properties or that of its rA2cp derivative. In addition, since the mean virus titers of rA2sites and rD46 are not significantly different, the six translationally silent L-gene site mutations do not appear to affect virus replication in this permissive host (Table 2, compare results for chimpanzees 1 to 4 with chimpanzees 7 to 10). Similarly, the HEK F-gene mutations do not appear to modify virulence (Table 2, compare results for chimpanzees 5 and 6 with chimpanzees 1 to 4 and 7 to 10). However, since the HEK-7 RSV was the genetic background for biologically derived cpRSV, it is possible that the cp mutations may interact with these HEK F-gene mutations. Since this is not directly tested here, the HEK F-gene mutations will be included with the cp mutations in future constructs.

Our approach to the development of a live attenuated vaccine virus is to sequentially introduce both ts and non-ts attenuating mutations into the genome of wt RSV until a proper balance between attenuation and immunogenicity has been achieved. The rationale for this design is based on the observation that several successful, live attenuated vaccines and vaccine candidates, including those for polioviruses, orthomyxoviruses, and paramyxoviruses, have ts mutations accompanied by non-ts mutations, both of which contribute to their attenuation (1, 8, 14, 17, 22, 23, 25). Because several live attenuated candidate vaccines that contain only ts mutations contributing to their attenuation readily undergo loss of their temperature sensitivity in animals or humans (7, 19, 22, 24), it was considered prudent to stabilize the ts and attenuation phenotypes of candidate RSV vaccines by combining both ts and non-ts attenuating mutations. Since the set of five cp mutations indeed specifies the attenuation phenotype, it represents our first non-ts attenuating genetic element for RSV. A second non-ts attenuating mutation, the deletion of the small hydrophobic (SH) protein of RSV, has also recently been identified (2). We are in the process of identifying the genetic basis of the attenuation and temperature sensitivity of a panel of ts viruses, such as cpts-248/404, cpts-530/1009, and cpts-530/1030, which were derived from cpRSV and show a range of phenotypes with regard to temperature sensitivity and attenuation (7, 8, 9, 11, 15). The ts mutations identified in these studies and the non-ts SH deletion mutation are currently being added individually and in combination to rA2cp to assess their contribution to attenuation and to create a new generation of novel live attenuated virus vaccine candidates. In this way, we believe that it will be possible to derive a satisfactorily attenuated and immunogenic RSV vaccine candidate in the near future.

Nucleotide sequence accession number. The nucleotide sequence of rA2cp has been submitted to the GenBank nucleotide sequence database and assigned accession no. AF035006.

    ACKNOWLEDGMENTS

We thank Robert Chanock, Anna Durbin, and Rachel Fearns for careful reviews of the manuscript.

This work is part of a continuing program of research and development with Wyeth-Lederle Vaccines and Pediatrics through CRADA no. AI-000030 and AI-000087.

    FOOTNOTES

* Corresponding author. Mailing address: LID, NIAID, 7 Center Dr., MSC 0720, Bethesda, MD 20892-0720. Phone: (301) 496-4205. Fax: (301) 496-8312. E-mail: sswhitehead{at}nih.gov.

    REFERENCES
Top
Abstract
Text
References

1. Bouchard, M. J., D.-H. Lam, and V. R. Racaniello. 1995. Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine. J. Virol. 69:4972-4978[Abstract].
2. Bukreyev, A., S. S. Whitehead, B. R. Murphy, and P. L. Collins. 1997. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J. Virol. 71:8973-8982[Abstract].
3. Chanock, R. M., and B. R. Murphy. 1991. Past efforts to develop safe and effective RSV vaccines, p. 35-42. In B. Meigner, B. Murphy, and P. Ogra (ed.), Animal models of respiratory syncytial virus infections. Merieux Foundation, Lyon, France.
4. Collins, P. L., M. G. Hill, E. Camargo, H. Grosfeld, R. M. Chanock, and B. R. Murphy. 1995. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc. Natl. Acad. Sci. USA 92:11563-11567[Abstract/Free Full Text].
5. Collins, P. L., K. McIntosh, and R. M. Chanock. 1996. Respiratory syncytial virus, p. 1313-1352. In B. N. Fields, D. M. Knipe, P. M. Howley, R. M. Chanock, J. L. Melnick, T. P. Monath, B. Roizman, and S. E. Straus (ed.), Fields virology, 3rd ed., vol. 2. Lippincott-Raven, Philadelphia, Pa.
6. Connors, M., J. E. Crowe, Jr., C.-Y. Firestone, B. R. Murphy, and P. L. Collins. 1995. A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes. Virology 208:478-484[Medline].
7. Crowe, J. E., Jr., P. T. Bui, A. R. Davis, R. M. Chanock, and B. R. Murphy. 1994. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine 12:783-790[Medline].
8. Crowe, J. E., Jr., P. T. Bui, W. T. London, A. R. Davis, P. P. Hung, R. M. Chanock, and B. R. Murphy. 1994. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Vaccine 12:691-699[Medline].
9. Crowe, J. E., Jr., P. T. Bui, G. R. Siber, W. R. Elkins, R. M. Chanock, and B. R. Murphy. 1995. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization. Vaccine 13:847-855[Medline].
10. Crowe, J. E., Jr., C. Y. Firestone, S. S. Whitehead, P. L. Collins, and B. R. Murphy. 1996. Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene. Virus Genes 13:269-273[Medline].
11. Firestone, C.-Y., S. S. Whitehead, P. L. Collins, B. R. Murphy, and J. E. Crowe, Jr. 1996. Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature-sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate. Virology 225:419-422[Medline].
12. Friedewald, W. T., B. R. Forsyth, C. B. Smith, M. A. Gharpure, and R. M. Chanock. 1968. Low-temperature-grown RS virus in adult volunteers. JAMA 203:690-694[Medline].
13. Grosfeld, H., M. G. Hill, and P. L. Collins. 1995. RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins; transcription also occurs under these conditions but requires RSV superinfection for efficient synthesis of full-length mRNA. J. Virol. 69:5677-5686[Abstract].
14. Hall, S. L., A. Stokes, E. L. Tierney, W. T. London, R. B. Belshe, F. C. Newman, and B. R. Murphy. 1992. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res. 22:173-184[Medline].
15. Juhasz, K., S. S. Whitehead, P. T. Bui, J. M. Biggs, C. A. Boulanger, P. L. Collins, and B. R. Murphy. 1997. The temperature-sensitive (ts) phenotype of a cold-passaged (cp) live attenuated respiratory syncytial virus vaccine candidate, designated cpts530, results from a single amino acid substitution in the L protein. J. Virol. 71:5814-5819[Abstract].
16. Karron, R. A., P. F. Wright, J. E. Crowe, Jr., M. L. Clements, J. Thompson, M. Makhene, R. Casey, and B. R. Murphy. 1997. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus (RSV) vaccines in chimpanzees, adults, infants and children. J. Infect. Dis. 176:1428-1436[Medline].
17. Kawamura, N., M. Kohara, S. Abe, T. Komatsu, K. Tago, M. Arita, and A. Nomoto. 1989. Determinants in the 5' noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J. Virol. 63:1302-1309[Abstract/Free Full Text].
18. Kim, H. W., J. O. Arrobio, G. Pyles, C. D. Brandt, E. Camargo, R. M. Chanock, and R. H. Parrott. 1971. Clinical and immunological response of infants and children to administration of low-temperature adapted respiratory syncytial virus. Pediatrics 48:745-755[Abstract/Free Full Text].
19. Murphy, B. R., E. J. Park, P. Gottlieb, and K. Subbarao. 1997. An influenza A live attenuated reassortant virus possessing three temperature-sensitive mutations in the PB2 polymerase gene rapidly loses temperature sensitivity following replication in hamsters. Vaccine 15:1372-1378[Medline].
19a. Peeples, M. E., and P. L. Collins. Unpublished data.
20. Sabin, A. B. 1961. Reproductive capacity of polioviruses of diverse origins at various temperatures, p. 90-110. In M. Pollard (ed.), Perspectives in virology II, vol. 2. Harper & Row, Publishers, Inc., New York, N.Y.
21. Schwarz, A. J. 1964. Immunization against measles: development and evaluation of a highly attenuated live measles vaccine. Ann. Paediatr. 202:241-252. [Medline]
22. Snyder, M. H., R. F. Betts, D. DeBorde, E. L. Tierney, M. L. Clements, D. Herrington, S. D. Sears, R. Dolin, H. F. Maassab, and B. R. Murphy. 1988. Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J. Virol. 62:488-495[Abstract/Free Full Text].
23. Tatem, J. M., C. Weeks-Levy, A. Georgiu, S. J. DiMichele, E. J. Gorgacz, V. R. Racaniello, F. R. Cano, and S. J. Mento. 1992. A mutation present in the amino terminus of Sabin 3 poliovirus VP1 protein is attenuating. J. Virol. 66:3194-3197[Abstract/Free Full Text].
24. Tolpin, M. D., J. G. Massicot, M. G. Mullinix, H. W. Kim, R. H. Parrott, R. M. Chanock, and B. R. Murphy. 1981. Genetic factors associated with loss of the temperature-sensitive phenotype of the influenza A/Alaska/77-ts-1A2 recombinant during growth in vivo. Virology 112:505-517[Medline].
25. Westrop, G. D., K. A. Wareham, D. M. A. Evans, G. Dunn, P. D. Minor, D. I. Magrath, F. Taffs, S. Marsden, M. A. Skinner, G. C. Schild, and J. W. Almond. 1989. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J. Virol. 63:1338-1344[Abstract/Free Full Text].

J Virol, May 1998, p. 4467-4471, Vol. 72, No. 5
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Hoffmann, E., Mahmood, K., Chen, Z., Yang, C.-F., Spaete, J., Greenberg, H. B., Herlocher, M. L., Jin, H., Kemble, G. (2005). Multiple Gene Segments Control the Temperature Sensitivity and Attenuation Phenotypes of ca B/Ann Arbor/1/66. J. Virol. 79: 11014-11021 [Abstract] [Full Text]  
  • Collins, P. L., Murphy, B. R. (2005). New Generation Live Vaccines against Human Respiratory Syncytial Virus Designed by Reverse Genetics. Proc Am Thorac Soc 2: 166-173 [Abstract] [Full Text]  
  • Spann, K. M., Collins, P. L., Teng, M. N. (2003). Genetic Recombination during Coinfection of Two Mutants of Human Respiratory Syncytial Virus. J. Virol. 77: 11201-11211 [Abstract] [Full Text]  
  • Neumann, G., Whitt, M. A., Kawaoka, Y. (2002). A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned?. J. Gen. Virol. 83: 2635-2662 [Abstract] [Full Text]  
  • Krempl, C., Murphy, B. R., Collins, P. L. (2002). Recombinant Respiratory Syncytial Virus with the G and F Genes Shifted to the Promoter-Proximal Positions. J. Virol. 76: 11931-11942 [Abstract] [Full Text]  
  • Zhang, L., Peeples, M. E., Boucher, R. C., Collins, P. L., Pickles, R. J. (2002). Respiratory Syncytial Virus Infection of Human Airway Epithelial Cells Is Polarized, Specific to Ciliated Cells, and without Obvious Cytopathology. J. Virol. 76: 5654-5666 [Abstract] [Full Text]  
  • Parks, C. L., Lerch, R. A., Walpita, P., Wang, H.-P., Sidhu, M. S., Udem, S. A. (2001). Analysis of the Noncoding Regions of Measles Virus Strains in the Edmonston Vaccine Lineage. J. Virol. 75: 921-933 [Abstract] [Full Text]  
  • Teng, M. N., Whitehead, S. S., Bermingham, A., St. Claire, M., Elkins, W. R., Murphy, B. R., Collins, P. L. (2000). Recombinant Respiratory Syncytial Virus That Does Not Express the NS1 or M2-2 Protein Is Highly Attenuated and Immunogenic in Chimpanzees. J. Virol. 74: 9317-9321 [Abstract] [Full Text]  
  • Tao, T., Skiadopoulos, M. H., Davoodi, F., Riggs, J. M., Collins, P. L., Murphy, B. R. (2000). Replacement of the Ectodomains of the Hemagglutinin-Neuraminidase and Fusion Glycoproteins of Recombinant Parainfluenza Virus Type 3 (PIV3) with Their Counterparts from PIV2 Yields Attenuated PIV2 Vaccine Candidates. J. Virol. 74: 6448-6458 [Abstract] [Full Text]  
  • Buchholz, U. J., Granzow, H., Schuldt, K., Whitehead, S. S., Murphy, B. R., Collins, P. L. (2000). Chimeric Bovine Respiratory Syncytial Virus with Glycoprotein Gene Substitutions from Human Respiratory Syncytial Virus (HRSV): Effects on Host Range and Evaluation as a Live-Attenuated HRSV Vaccine. J. Virol. 74: 1187-1199 [Abstract] [Full Text]  
  • Peeples, M. E., Collins, P. L. (2000). Mutations in the 5' Trailer Region of a Respiratory Syncytial Virus Minigenome Which Limit RNA Replication to One Step. J. Virol. 74: 146-155 [Abstract] [Full Text]  
  • Whitehead, S. S., Hill, M. G., Firestone, C. Y., St. Claire, M., Elkins, W. R., Murphy, B. R., Collins, P. L. (1999). Replacement of the F and G Proteins of Respiratory Syncytial Virus (RSV) Subgroup A with Those of Subgroup B Generates Chimeric Live Attenuated RSV Subgroup B Vaccine Candidates. J. Virol. 73: 9773-9780 [Abstract] [Full Text]  
  • Tripp, R. A., Moore, D., Jones, L., Sullender, W., Winter, J., Anderson, L. J. (1999). Respiratory Syncytial Virus G and/or SH Protein Alters Th1 Cytokines, Natural Killer Cells, and Neutrophils Responding to Pulmonary Infection in BALB/c Mice. J. Virol. 73: 7099-7107 [Abstract] [Full Text]  
  • Juhasz, K., Murphy, B. R., Collins, P. L. (1999). The Major Attenuating Mutations of the Respiratory Syncytial Virus Vaccine Candidate cpts530/1009 Specify Temperature-Sensitive Defects in Transcription and Replication and a Non-Temperature-Sensitive Alteration in mRNA Termination. J. Virol. 73: 5176-5180 [Abstract] [Full Text]  
  • Whitehead, S. S., Bukreyev, A., Teng, M. N., Firestone, C.-Y., St. Claire, M., Elkins, W. R., Collins, P. L., Murphy, B. R. (1999). Recombinant Respiratory Syncytial Virus Bearing a Deletion of either the NS2 or SH Gene Is Attenuated in Chimpanzees. J. Virol. 73: 3438-3442 [Abstract] [Full Text]  
  • Whitehead, S. S., Firestone, C.-Y., Karron, R. A., Crowe, J. E. Jr., Elkins, W. R., Collins, P. L., Murphy, B. R. (1999). Addition of a Missense Mutation Present in the L Gene of Respiratory Syncytial Virus (RSV) cpts530/1030 to RSV Vaccine Candidate cpts248/404 Increases Its Attenuation and Temperature Sensitivity. J. Virol. 73: 871-877 [Abstract] [Full Text]  
  • Skiadopoulos, M. H., Surman, S., Tatem, J. M., Paschalis, M., Wu, S.-L., Udem, S. A., Durbin, A. P., Collins, P. L., Murphy, B. R. (1999). Identification of Mutations Contributing to the Temperature-Sensitive, Cold-Adapted, and Attenuation Phenotypes of the Live-Attenuated Cold-Passage 45 (cp45) Human Parainfluenza Virus 3 Candidate Vaccine. J. Virol. 73: 1374-1381 [Abstract] [Full Text]  
  • Teng, M. N., Collins, P. L. (1999). Altered Growth Characteristics of Recombinant Respiratory Syncytial Viruses Which Do Not Produce NS2 Protein. J. Virol. 73: 466-473 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Whitehead, S. S.
Right arrow Articles by Murphy, B. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Whitehead, S. S.
Right arrow Articles by Murphy, B. R.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»